{"title":"2019冠状病毒病大流行期间高分辨率计算机断层扫描诱发乳腺癌的终生归因风险","authors":"Roya Sahebi, Jafar Hassanzadeh, Rezvan Ravanfar Haghighi, Mehrzad Lotfi, Alireza Mirahmadizadeh","doi":"10.18502/jfrh.v18i4.17429","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The widespread utilization of high-resolution computed tomography (HRCT) for diagnosing and management of COVID-19 during the pandemic has prompted worries regarding a potential rise in future breast cancer cases. We aimed to estimate the Life Attributable Risk (LAR) of breast cancer in Shiraz, Iran, linked to HRCT use during the COVID-19 pandemic.</p><p><strong>Materials and methods: </strong>A cross-sectional study was conducted at Namazi Hospital in Shiraz from February 2, 2020, to December 31, 2022.The Imaging Performance Assessment of CT Scanners (ImPACT) patient dosimetry calculator was used to determine organ doses. LAR was computed utilizing the Biological Effects of Ionizing Radiation (BEIR) Committee models.</p><p><strong>Results: </strong>The sample size was 666, with ages spanning from 15 to 95 years. 25% (168) had HRCT more than once (2 to 8 times). The mean and 95% uncertainty limits (UL) for Total LAR of breast cancer, considering both single and multiple doses of radiation exposure, was 217 (95% UL, 194-244) per 100,000 persons.</p><p><strong>Conclusion: </strong>According to our research, the risk of potential breast cancer should not be overlooked. It is advised to use the ultra-low-dose protocol over the low-dose in HRCT. Physicians, pulmonologists, and infectious disease specialists are advised to avoid unnecessary and repeated requests for chest HRCT in a short period.</p>","PeriodicalId":15845,"journal":{"name":"Journal of Family and Reproductive Health","volume":"18 4","pages":"274-280"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056439/pdf/","citationCount":"0","resultStr":"{\"title\":\"Lifetime Attributable Risk for Breast Cancer Induced by High-Resolution Computed Tomography During COVID-19 Pandemic.\",\"authors\":\"Roya Sahebi, Jafar Hassanzadeh, Rezvan Ravanfar Haghighi, Mehrzad Lotfi, Alireza Mirahmadizadeh\",\"doi\":\"10.18502/jfrh.v18i4.17429\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The widespread utilization of high-resolution computed tomography (HRCT) for diagnosing and management of COVID-19 during the pandemic has prompted worries regarding a potential rise in future breast cancer cases. We aimed to estimate the Life Attributable Risk (LAR) of breast cancer in Shiraz, Iran, linked to HRCT use during the COVID-19 pandemic.</p><p><strong>Materials and methods: </strong>A cross-sectional study was conducted at Namazi Hospital in Shiraz from February 2, 2020, to December 31, 2022.The Imaging Performance Assessment of CT Scanners (ImPACT) patient dosimetry calculator was used to determine organ doses. LAR was computed utilizing the Biological Effects of Ionizing Radiation (BEIR) Committee models.</p><p><strong>Results: </strong>The sample size was 666, with ages spanning from 15 to 95 years. 25% (168) had HRCT more than once (2 to 8 times). The mean and 95% uncertainty limits (UL) for Total LAR of breast cancer, considering both single and multiple doses of radiation exposure, was 217 (95% UL, 194-244) per 100,000 persons.</p><p><strong>Conclusion: </strong>According to our research, the risk of potential breast cancer should not be overlooked. It is advised to use the ultra-low-dose protocol over the low-dose in HRCT. Physicians, pulmonologists, and infectious disease specialists are advised to avoid unnecessary and repeated requests for chest HRCT in a short period.</p>\",\"PeriodicalId\":15845,\"journal\":{\"name\":\"Journal of Family and Reproductive Health\",\"volume\":\"18 4\",\"pages\":\"274-280\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056439/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Family and Reproductive Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/jfrh.v18i4.17429\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Family and Reproductive Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/jfrh.v18i4.17429","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Lifetime Attributable Risk for Breast Cancer Induced by High-Resolution Computed Tomography During COVID-19 Pandemic.
Objective: The widespread utilization of high-resolution computed tomography (HRCT) for diagnosing and management of COVID-19 during the pandemic has prompted worries regarding a potential rise in future breast cancer cases. We aimed to estimate the Life Attributable Risk (LAR) of breast cancer in Shiraz, Iran, linked to HRCT use during the COVID-19 pandemic.
Materials and methods: A cross-sectional study was conducted at Namazi Hospital in Shiraz from February 2, 2020, to December 31, 2022.The Imaging Performance Assessment of CT Scanners (ImPACT) patient dosimetry calculator was used to determine organ doses. LAR was computed utilizing the Biological Effects of Ionizing Radiation (BEIR) Committee models.
Results: The sample size was 666, with ages spanning from 15 to 95 years. 25% (168) had HRCT more than once (2 to 8 times). The mean and 95% uncertainty limits (UL) for Total LAR of breast cancer, considering both single and multiple doses of radiation exposure, was 217 (95% UL, 194-244) per 100,000 persons.
Conclusion: According to our research, the risk of potential breast cancer should not be overlooked. It is advised to use the ultra-low-dose protocol over the low-dose in HRCT. Physicians, pulmonologists, and infectious disease specialists are advised to avoid unnecessary and repeated requests for chest HRCT in a short period.
期刊介绍：
The Journal of Family & Reproductive Health (JFRH) is the quarterly official journal of Vali–e–Asr Reproductive Health Research Center. This journal features fulllength, peerreviewed papers reporting original research, clinical case histories, review articles, as well as opinions and debates on topical issues. Papers published cover the scientific and medical aspects of reproductive physiology and pathology including genetics, endocrinology, andrology, embryology, gynecologic urology, fetomaternal medicine, oncology, infectious disease, public health, nutrition, surgery, menopause, family planning, infertility, psychiatry–psychology, demographic modeling, perinatalogy–neonatolgy ethics and social issues, and pharmacotherapy. A high scientific and editorial standard is maintained throughout the journal along with a regular rate of publication. All published articles will become the property of the JFRH. The editor and publisher accept no responsibility for the statements expressed by the authors here in. Also they do not guarantee, warrant or endorse any product or service advertised in the journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
